首页> 外文期刊>British Journal of Pharmacology >Effects of U46619 on contractions to 5-HT, sumatriptan and meethysergide in canine coronary artery and saphenous vein in vitro
【24h】

Effects of U46619 on contractions to 5-HT, sumatriptan and meethysergide in canine coronary artery and saphenous vein in vitro

机译:U46619对犬冠状动脉和隐静脉中5-HT,舒马曲坦和甲磺酰胺的收缩的影响

获取原文
获取原文并翻译 | 示例
       

摘要

1 The aim of this study was to investigate the mechanism of enhanced reactivity to 5-hydroxytryptamine (5-HT) and sumatriptan previously observed in human isolated coronary arteries when active force was raised with the thromboxane A_2-mimetic, U46619. 2 Ring segments of dog isolated coronary artery and saphenous vein were suspended in organ baths and cumulative concentration-contraction curves to 5-HT, sumatriptan and methysergide were constructed in the absence and presence of low concentrations of U46619. 3 In both endothelium-intact and endothelium-denuded rings of coronary artery, precontraction with U46619 to low (< 10% F_(max); the contraction to a maximum depolarizing 125 mM KCl Krebs solution; KPSS) levels of active force had no effect on either the maximum contraction or sensitivity (pEC_(50)) to 5-HT, sumatriptan and methysergide. 4 Ketanserin (1 μM) had no effect on contractions to sumatriptan and methysergide in endothelium-denuded coronary artery rings, but reduced the maximum contraction to 5-HT by ≈ 90% to a value (5% F(max)) similar to that for sumatriptan and methysergide. Under these conditions, U46619 precontraction had no effect on either pEC_(50) or maximum for 5-HT, sumatriptan or methysergide. 5 In rings of saphenous vein with endothelium and treated with ketanserin (1 μM), 5-HT and sumatriptan caused equal maximum responses of 65% F_(max) which were approximately double that of methysergide (32% F_(max)). The maximum responses and sensitivity to 5-HT, sumatriptan, methysergide and noradrenaline were unaffected by precontraction with U46619. 6 Pretreatment of the saphenous vein with sodium nitroprusside (SNP; 10 μM) caused a small sustained relaxation and significantly depressed the maximal contraction to 5-HT without affecting sensitivity and abolished the contraction curve to sumatriptan and methysergide. When the relaxation response to SNP was reversed with U46619 (1-4 nM), the contraction curves to 5-HT, sumatriptan and methysergide were similar to those obtained prior to relaxation with SNP. In contrast, the same treatment with SNP had little affect on the contraction curve to noradrenaline. 7 In conclusion, the pattern of U46619-enhanced reactivity of 5-HT, sumatriptan and methysergide in SNP-treated dog saphenous vein, highlights the importance of functional antagonism when assessing reactivity to contractile agonists in isolated blood vessels.
机译:1这项研究的目的是研究当血栓烷A_2-模拟物U46619产生主动力时,在人类分离的冠状动脉中观察到的对5-羟色胺(5-HT)和舒马普坦增强反应性的机制。将犬分离的冠状动脉和大隐静脉的2个环段悬挂在器官浴中,在不存在和存在低浓度U46619的情况下,绘制5-HT,舒马普坦和美塞麦肽的累积浓度-收缩曲线。 3在冠状动脉的完整内皮环和内皮剥脱环中,用U46619预收缩至低(<10%F_(max);收缩至最大去极化125 mM KCl Krebs溶液; KPSS)水平的主动力均无效对5-HT,舒马曲坦和美塞麦肽的最大收缩或敏感性(pEC_(50))。 4 Ketanserin(1μM)对内皮剥除的冠状动脉环中舒马曲坦和美塞麦肽的收缩没有影响,但对5-HT的最大收缩降低了≈90%,至与该值相似的值(5%F(max))用于舒马普坦和美塞麦肽。在这些条件下,U46619的预收缩对pEC_(50)或5-HT,舒马曲坦或美塞麦肽的最大值均无影响。 5在带有内皮并用酮色林(1μM)处理的大隐静脉环中,5-HT和舒马曲坦引起的最大等效反应为65%F_(max),大约是美塞麦肽(32%F_(max))的两倍。 U46619的预收缩不影响对5-HT,舒马曲坦,美塞麦肽和去甲肾上腺素的最大反应和敏感性。 6用硝普钠(SNP; 10μM)对隐静脉进行预处理可引起较小的持续舒张,并显着降低了对5-HT的最大收缩,而不会影响敏感性,并且消除了舒马普坦和美塞麦肽的收缩曲线。当用U46619(1-4 nM)逆转对SNP的松弛反应时,对5-HT,舒马曲坦和美塞麦肽的收缩曲线与在用SNP松弛之前获得的收缩曲线相似。相反,相同的SNP治疗对去甲肾上腺素的收缩曲线影响很小。 7总之,在评估对孤立血管中收缩性激动剂的反应性时,SNP处理的犬大隐静脉中5-HT,舒马曲坦和甲基麦角胺的U46619增强反应性的模式突显了功能拮抗作用的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号